Home › PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
 

Keywords :   


PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia

2015-11-03 03:42:29| drugdiscoveryonline Home Page

PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)

Tags: corporation drug submission announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Reddit shares jump after OpenAI ChatGPT deal
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
17.05Pornhub partners with UK child abuse fighting charity
More »